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Abstract
Background—Pre-clinical evidence supports the clinical investigation of inhibitors to the 
insulin-like growth factor receptor (IGFR) and the epidermal growth factor receptor (EGFR) alone 
and in combination in patients with NSCLC.
Patients and Methods—Patients with chemotherapy-naïve, advanced NSCLC and an ECOG 
performance status (PS) 0/1 were eligible. Patients were randomized to receive: carboplatin AUC 
6 iv + paclitaxel 200 mg/m2 iv on day 1 every 3 weeks combined with either cetuximab (CET) iv 
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weekly (arm A), cixutumumab (CIX) iv every 2 weeks (arm B), or both (arm C). Patients with 
non-progressive disease (PD) after 12 weeks of therapy were permitted to continue on 
maintenance antibody therapy until PD. The primary endpoint was progression-free survival 
(PFS). The design required 180 eligible patients and had an 88% power to detect a 60% increase 
in median PFS for either comparison (arm A vs C or arm B vs C) using the log-rank test.
Results—From 9/09 until 12/10, 140 patients were accrued. The study was closed to accrual 
early because of excessive number of grade 5 events reported on arms A and C. Thirteen patients 
died during treatment (A=6; B=2; C=5), including 9 within approximately 1 month of starting 
therapy. The estimated median PFS for arms A/B/C were similar at 3.4, 4.2, and 4 months, 
respectively.
Conclusions—Based upon the apparent lack of efficacy and excessive premature deaths, this 
study does not support the continued investigation of carboplatin + paclitaxel + CIX alone or in 
combination with CET in patients with advanced NSCLC.
Introduction
Molecularly targeted agents are becoming an important component of therapy in the 
management of some patients with advanced non-small cell lung cancer (NSCLC). One of 
the hallmarks of cancer is the dysregulation of growth signaling pathways (1). Inhibition of 
the epidermal growth factor receptor (EGFR) pathway has been validated in some patients 
with advanced NSCLC (2). In one phase III study, patients with advanced NSCLC 
randomized to receive chemotherapy with or without cetuximab, a monoclonal antibody to 
EGFR, demonstrated a modest improvement survival with the addition of cetuximab, 
although this was not sufficient to lead to regulatory approval (3). Another study of 
carboplatin plus a taxane with and without cetuximab demonstrated a numerically higher 
overall survival (p=NS) for the cetuximab-containing arm (4).
In recent years the insulin-like growth factor (IGF) has been studied to understand its’ role 
in the development, pathogenesis, and progression of lung cancer. Signaling through the IGF 
receptor (IGFR) pathway occurs primarily through the phosphatidylinositol-3 kinase (PI3K)-
Akt pathway and the mitogen-activated protein kinase (MAPK) pathway, resulting in 
increased cell proliferation and inhibition of apoptosis (5–7). Deregulation of the IGF 
pathway appears to result in an increased risk of lung cancer, decreased survival in patients 
with stage I disease, and facilitation of malignant transformation (8–11). Synergistic activity 
of IGF-1R inhibitors and cytotoxic agents has been described, establishing the rationale for 
combining IGFR inhibitors with chemotherapy (12). In addition, outcomes of nude mice 
bearing A549 NSCLC tumors treated with the anti-IGF-1R antibody h7C10 combined with 
chemotherapy or the anti-EGFR antibody, cetuximab, were superior to those of mice treated 
with either agent alone (12). The rationale for combining EGFR and IGFR inhibitors is 
further supported by additional studies which implicate the expression of IGF-1R with a 
reduced efficacy of anti-EGFR targeting, including resistance to gefitinib (13–15). Other 
pathway activation, including AKT signaling, has been associated with resistance to EGFR 
inhibitors (16). Combining IGF-1R inhibition with EGFR inhibition may reduce this AKT 
pathway activity (16).
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Monoclonal antibodies, including the fully human IgG1 antibody Cixutumumab, have been 
developed to deregulate the IGF pathway. In vitro, treatment with Cixutumumab induces 
apoptosis in human xenograft models and demonstrates increased cytotoxicity when 
combined with EGFR inhibition (17). A randomized phase II study comparing patients 
treated with chemotherapy +/− IGFR inhibition originally reported higher response rates 
(although subsequently retracted in 2012) for those receiving the anti-IGFR therapy (18). 
Therefore, based upon pre-clinical and early clinical information, we conducted this 
randomized phase II study to evaluate the efficacy of chemotherapy combined with EGFR 
inhibition or IGFR inhibition or both in patients with advanced NSCLC who are not 
receiving bevacizumab-based therapy.
Patients and Methods
Eligibility
To be eligible, patients must have had a diagnosis of NSCLC, measurable (as defined by 
RECIST version 1.1) stage IV disease (including M1a and M1b according to the 7th edition 
of the TNM classification system) or T4NX (stage IIIB) defined by a nodule in the 
ipsilateral lung lobe, if not a candidate for combined chemotherapy and radiation or surgery. 
Patients must have not received prior systemic therapy, including bevacizumab, anti-EGFR 
or anti-IGFR therapy, for advanced disease. Patients receiving neo-adjuvant or adjuvant 
chemotherapy were eligible if more than 1 year had passed prior to randomization to this 
trial. All patients had an ECOG PS of 0 or 1. Patients were not eligible if they had untreated 
or symptomatic central nervous system (CNS) metastases. Patients with a history of CNS 
metastases that were both definitively treated and stably controlled were eligible. Patients 
were also excluded if they had major surgery within 4 weeks prior to randomization, history 
of interstitial pneumonitis or pulmonary fibrosis, uncontrolled hypertension or cardiac 
disease, synchronous malignancy within the last 3 years or those thought to be of a low risk 
for recurrence definitively treated < 3 years prior to randomization, serum fasting glucose of 
> 120 mg/dL or above the institutional upper limits of normal (ULN) within 2 weeks prior to 
randomization, poorly controlled diabetes mellitus, history of allergic reactions attributed to 
compounds of similar chemical or biological composition to cixutumumab, history of 
arterial thrombosis, pulmonary embolus, deep venous thrombosis or hemorrhagic disorders 
<28 days prior to randomization, or peripheral neuropathy > grade 1 as per the CTCAE 
version 4 grading scale. Within 2 weeks prior to randomization, partial thromboplastin time 
(PTT) < 1.2 × ULN and international normalized ratio (INR) ≤ 1.5 was required. Patients 
must have had normal hepatic, renal, and bone marrow function. Written informed consent 
was obtained from all participants.
Study Design, Endpoints, and Treatment
This was a multi-center, randomized trial conducted by ECOG. The primary objective was 
to evaluate the progression-free survival (PFS) of patients with NSCLC randomized to 
carboplatin plus paclitaxel plus either cetuximab (arm A), cixutumumab (arm B), or both 
(arm C). The secondary objectives included evaluation of response rate, disease control rate 
(complete response plus partial response plus stable disease), overall survival, and toxicities. 
Additional secondary objectives included evaluating EGFR by immunohistochemistry 
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(IHC), mutation, and gene copy number, IGF-1R and IGF-2R expression, and KRAS 
mutation. Plasma-based biomarkers were also evaluated for total and free IGF-1 and IGF-2, 
and IGF-growth factor binding protein 3 (IGFBP3).
The treatment schema for this trial is displayed in Figure 1. Each treatment cycle lasted 6 
weeks (42 days). Patients were randomized to receive carboplatin AUC=6 i.v. plus 
paclitaxel 200 mg/m2 i.v. on days 1 and 22 of each cycle in combination with either 
cetuximab 250 mg/m2 i.v. days 1, 8, 15, 22, 29, and 36 of each cycle (Arm A) or 
cixutumumab 10 mg/kg i.v. on days 1, 15, and 29 of each cycle (Arm B), or the combination 
of cetuximab and cixutumumab (Arm C) at the dose and schedule specified for these 
therapies on arms A and B, respectively. The loading dose for patients receiving cetuximab 
was 400 mg/m2 i.v. on day 1 of cycle 1 only. After two 6-week cycles of induction therapy, 
patients who had not progressed continued onto maintenance therapy of cetuximab, 
cixutumumab, or both corresponding to their treatment assignment per randomization until 
disease progression or unacceptable toxicity. Imaging studies were conducted at baseline 
and at each 6 week treatment interval.
Tumor samples were analyzed by immunohistochemistry (IHC; EGFR, IGF-1R and IGF-2R 
expression), fluorescent in-situ hybridization (FISH; EGFR gene copy number) and DNA 
sequencing (EGFR, KRAS gene mutations). FISH scores were interpreted according to the 
Colorado Scoring Criteria (19).
Statistical Considerations
This 3-arm study planned to randomize 180 eligible and treated patients (200 total patients 
after 10% inflation for ineligibility) over 12 months with 9 additional months of follow-up 
to compare the combination of cixutumumab and cetuximab (Arm C) to each of the single 
agents (Arms A and B) without a formal comparison between the cetuximab alone (Arm B) 
and cixutumumab alone (Arm C) arms. This design had a yield of 88% power to detect a 
60% increase in median PFS (5.6 months vs. 3.5 months) for either comparison at the 1-
sided 0.10 significance level using the log rank test. Full information would be reached at 
108 PFS events in each comparison. There was no plan to compare the experimental arms to 
each other.
Safety data on patients and a comparison of toxicity rates of each arm was collected and an 
interim safety analysis was planned among the first 20 patients who completed the initial 3 
cycles of treatment. Early stopping rules were defined by 6 or more events of any grade 3 or 
higher non-hematological toxicity, any grade 4 or higher hematological toxicity, or grade 3 
or higher febrile neutropenia or infection with neutropenia.
Archived tissue and serum was obtained from all patients who consented to participate in the 
exploratory laboratory research studies. Assuming 75% of patients would participate in the 
correlative studies and have analyzable samples for study, the estimated sample size for the 
correlative study was 135 patients. For the correlative endpoints to cetuximab (EGFR and K-
Ras) we anticipated that the mutation rate of this population would be 15%. Among the 135 
expected samples, 90 of these patients would have received cetuximab and 45 would have 
been randomized to the cixutumumab alone arm. Therefore, 14 of the 90 patients receiving 
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cetuximab were expected to have a mutation. Assuming a one-sided type I error rate of 0.10, 
this sample size provided 81% power to detect a 100% improvement in the median PFS 
from 3 months in the mutation negative group to 6 months in the mutation positive group 
among those patients treated with cetuximab. For the correlative endpoints specific to 
cixutumumab (IGF-1R and IGF-2R) the anticipated expression rate was assumed to be 50%. 
Among the 135 expected samples, 90 of these patients will have received cixutumumab. 
Therefore, 45 of 90 patients receiving cixutumumab were expected to have positive 
expression levels. Assuming a one-sided type I error rate of 0.10, this sample size provided 
96% power to detect a 100% improvement in the median PFS from 3 months in the zero 
expressing group to 6 months in the expression positive group among those treated with 
cixutumumab.
Overall survival was defined at the time from randomization to death from any cause, with 
follow-up censored at the date of last contact. Objective response was evaluated using 
RECIST 1.1 criteria. PFS was defined to be the time from randomization to death or 
documented disease progression, whichever occurred first. Patients that were alive at the 
time of analysis were censored at the date at which they were last known to be alive and 
progression-free.
Kaplan-Meier curves were used to estimate event-time distributions. Cox proportional 
hazards model, stratified on gender and histology (squamous vs. non-squamous) were used 
to estimate hazard ratios and test for significance for PFS. PFS and OS were compared using 
logrank tests. Adverse events, patient demographics, disease characteristics and response 
rates were compared using Fisher’s exact tests. All p-values are two-sided and confidence 
intervals are at the 95% level. Correlative studies were conducted using similar analysis 
methodology.
Results
From September 11, 2009 through December 17, 2010, one-hundred and forty patients were 
accrued. The study was subsequently terminated on April 11, 2011 due to excessive grade 5 
events within 30 days of registration. Table 1 summarizes the patient demographics and 
disease characteristics. There were no substantial differences between the arms. The 
majority of patients had male gender and white race, as well as ECOG PS 0 and < 5% 
weight loss in the previous 6 months. Similar rates of squamous and non-squamous 
histology were represented. The percentage of patients receiving at least 2 cycles (12 weeks) 
of therapy were 51%, 69%, and 60% for arms A, B, and C, respectively. The percentage of 
patients receiving at least 4 cycles (24 weeks) of therapy were 26%, 26%, and 17% for Arms 
A, B, and C, respectively.
An interim safety analysis was conducted in November 2010 after approximately 20 patients 
were randomized to each arm and had completed 3 cycles of treatment. At that time, the 
study was accruing more rapidly than anticipated and a follow-up call was schedule for 
December 2010, after more toxicity data had been submitted and further analyses conducted. 
The study was suspended for excessive grade 5 events within 30 days of registration at that 
time, on December 17, 2010. A full review of all available data was then conducted and 
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reviewed, resulting in termination to accrual on April 19, 2011. At the time of the safety 
analysis, there was found a higher-than-expected rate of adverse events on Arm C, which 
included deaths for which a treatment-related attribution could not be excluded. In addition, 
there was a higher-than-expected rate of early deaths on arm A. However, a review of these 
deaths identified that disease, not treatment-related complications, was the likely cause of 
death in most of the cases. Therefore, all patients on Arm C discontinued therapy. All 
patients on Arms A and B may have continued therapy according to the protocol at the 
discretion of the study participant and the treating physician.
All toxicities, regardless of attribution and including grade 5 events, are summarized in 
Table 2. In total, 6 deaths were reported on arm A, 3 on arm B, and 5 on arm C. Deaths on 
Arm A were attributed to asystole in 1 patient, lung infection or respiratory failure in 2 
patients, colitis in 1 patient, and unspecified reasons in the other 2. On Arm B, 2 deaths were 
for unspecified reasons and 1 death was due to cancer. On arm C, 3 deaths were attributed to 
pulmonary disease (hypoxia, respiratory failure, acute respiratory distress syndrome), and 2 
were unspecified. Grade 3/4 neutropenia was reported in 29%, 30%, and 42% for arms 
A/B/C, respectively; however, grade 3/4 febrile neutropenia was reported in only 7%, 4.5%, 
and 4.2% for arms A/B/C, respectively. Grade 3/4 hyperglycemia was more common on the 
cixutumumab-containing arms (14–17%) compared with arm A (2%). In addition, more 
patients on arm C experienced grade 3/4 hyponatremia (17%) compared with arms A or B 
(2% and 4.5%, respectively).
At the time of data analysis, 111 of 127 eligible and treated patients had died and a total of 
123 patients experienced a PFS event. The median follow-up on patients still alive (n=18) 
was 31 months. The estimated median PFS and corresponding 95% CI on each treatment 
arm was 3.4 months (2.6–5.8), 4.2 months (3.5–5.3), and 4 months (3.2–5.4), for arms A, B, 
and C, respectively (Figure 2). Arm C did not improve PFS compared to arm A (HR 1.12, 
95% CI (0.71–1.78), p=0.62) or arm B (HR 1.10, 95% CI (0.71–1.72), p=0.67). The 
estimated median OS and corresponding 95% CI on each treatment arm was 9.8 months 
(7.4–17.2), 7.7 months (5.8–11.5), and 8.8 months (7.2–14.9) for arms A, B, and C, 
respectively (Figure 3). The response rate for arm A, B, and C, were 11%, 22%, and 22%, 
respectively. The disease control rate for arms A, B, and C, were 47%, 63%, and 63%, 
respectively.
Results of Exploratory Correlative Studies
This study was underpowered to detect differences in subsets defined by biomarker studies. 
When EGFR was analyzed by FISH, there were 5 failures, while 39 tested negative and 30 
tested positive according to criteria described previously (20). The median OS for EGFR 
negative and positive (by FISH) was 8.6 months (95% CI 6.4–12) and 9.5 months (95% CI 
6.8–26.7), respectively, log rank p=0.06. There was no difference in these groups’ PFS (log 
rank p=0.18); similarly, no differences were observed by whether or not cetuximab was 
received.
For EGFR mutation status, exons 18–21 were evaluated but no mutations were found except 
in 5 patients harboring an exon 19 mutation. No significant differences were observed in 
their outcomes compared to those without mutation.
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KRAS genotyping was conducted, and the numbers of patients tested was too small for 
statistical testing. For codon 12.34, 72 patients had the GG genotype, while 7 had the GT 
genotype, 1 had GC, 4 had GA, and 1 had TT. For codon 12.35, 8 patients had the GC 
genotype, while 73 had the GG genotype; 2 had the GA genotype and 1 had the GT 
genotype. For codon 13.38, 5 patients had the GA genotype, while 79 had the GG genotype. 
For codons 61.182 and 61.183, all patients had the AA genotype. A total of 23 patients 
(among 85) had a mutation in any of the above mentioned codons, but comparisons of OS 
and PFS were not significant.
IHC studies reported no significant differences when compared by treatment arm or by 
group when the protein expression was dichotomized as positive (≥ 200) and negative using 
the H-score system (21). Median IGF-1R score was 190 (range 30–390); median IGF-2R 
score was 145 (range 20–350); median EGFR membrane and cytoplasm H score was 190 
(range 0–380); and median EGFR membrane H scores was 160 (range 0–390).
Discussion
Results from this randomized, open-label, multi-institutional, phase II study do not support 
continued evaluation of cixutumumab in combination with carboplatin plus paclitaxel with 
or without cetuximab in the patient population studied. The study did not meet its primary 
endpoint of demonstrating improved PFS with the cixutumumab-containing regimens 
compared with carboplatin plus paclitaxel plus cetuximab regimen. While response rates and 
disease control rates trended higher with the 2 cixutumumab-containing arms compared with 
the carboplatin/paclitaxel/cetuximab arm, neither PFS nor OS appeared superior with the 
cixutumumab-containing arms. Patient characteristics were similar between 3 arms with the 
exception of more active smokers in the cetuximab + cixutumumab-containing arm. Disease 
characteristics were also similar between each arm. A few toxicity differences were noted 
between the arms. More grade 3 hyponatremia was observed in the cetuximab-
cixutumumab-containing arm and, as expected, more grade 3 and 4 hyperglycemia was 
reported in the cixutumumab-containing arms. While more grade 3/4 neutropenia was 
reported on the cetuximab-cixutumumab-containing arm there was no difference in febrile 
neutropenia or infection rates amongst the arms.
The trial was closed prior to planned accrual goals due to concerns about excessive grade 5 
events reported for arm A and C. A detailed analysis of each death did not demonstrate a 
clear pattern of causality. Excessive grade 5 events had not been previously reported in 
larger phase III trials of chemotherapy with cetuximab, including in combination with 
carboplatin and paclitaxel (3, 4). While excessive grade 5 events were not reported on arm 
B, accrual was halted based on a consensus opinion of the leaders of the study, including 
ECOG members as well as members of NCI/CTEP. Reasons for this decision included the 
recently reported negative phase III study with figitumumab (monoclonal antibody targeting 
the insulin-like growth factor-1 receptor), which failed to confirm the promising results 
reported in the randomized phase II study (22). Our study was designed prior to knowing the 
results of the phase III trial with figitumumab (22). In that trial, the DSMC recommended 
early closure due to futility, but also excessive toxicity, including 5% grade 5 events in the 
figitumumab arm.
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Biomarker studies are an integral component of trials assessing molecularly targeted 
therapy. While unselected patient populations may not benefit from a given targeted therapy, 
correlation of outcomes with molecular targets may identify a subpopulation of patients 
likely to benefit. The best examples to date in NSCLC include the identification of EGFR 
mutations that predict response to EGFR tyrosine kinase inhibitors and ALK gene re-
arrangements, which predict response to ALK tyrosine kinase inhibitors (23–25). 
Unfortunately, biomarker studies (which were exploratory and presumably compromised 
further due to early study closure) of the current trial did not provide additional insights into 
subgroups of patients who may benefit from cixutumumab-containing regimens.
In vitro and in vivo studies supported the clinical testing of combination studies of IGF-1R 
and EGFR dual inhibition (11, 12). Results from a phase I/II study of erlotinib in 
combination with cixutumumab in patients with advanced NSCLC (most had received 1 or 
more prior regimens) was reported by Weickhardt et al in 2012 (26). Patients were treated in 
a dose-escalation manner (3+3 design). The most frequent AE’s were fatigue, rash, diarrhea, 
anorexia, and nausea. Of 18 patients evaluated, 5 achieved stable disease, including 1 patient 
who had SD for > 14 months. There appeared to be little activity in an unselected EGFR-
wild type patient population. Biomarker analysis on this small study demonstrated a trend 
towards benefit in PFS for patients with the highest quartile of baseline free IGF-1.
In the first line setting Karp et al initially reported promising results from a randomized 
phase II study of carboplatin plus paclitaxel plus or minus figitumumab (antibody to IGFR) 
(18). Since this initial report, results from this study were published in 2009, but 
subsequently retracted in 2012, when the sponsor learned that the overall response rate and 
PFS data was incorrect (27,28). Additionally, a phase III study of figitumumab in 
combination with carboplatin plus paclitaxel in a non-adenocarcinoma patient population, 
failed to demonstrate increased efficacy with the addition of figitumumab (22). In this trial, 
681 patients were enrolled, most of whom had squamous cell cancer (86%). The HR crossed 
the pre-specified futility boundary of 1.1 favoring paclitaxel and carboplatin alone. In those 
with low baseline IGF levels, safety, tolerability, and survival appeared worse with the 
addition of figitumumab to carboplatin and paclitaxel.
In conclusion, treatment with cixutumumab in combination with carboplatin plus paclitaxel 
with or without cetuximab does not appear to improve PFS or OS in the unselected patient 
population tested in our study. Prior studies, as detailed above, hypothesize the level of 
circulating IGF levels may impact therapies that block IGFR activity. Future studies, if any 
are to be conducted in NSCLC, should only be conducted if a biomarker, such as high 
circulating IGF levels, is used to select potentially responsive patients.
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Figure 1. E4508 Schema
This figure provides the treatment regimen, schedule, and stratification factors
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Figure 2. Profression-free survival
This figure provides the Kaplan-Meier curves for progression-free survival of the 3 arms
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Figure 3. Overall survival
This figure provides the Kaplan-Meier curves for overall survival of the 3 arms
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